section name header

Pronunciation

tha-LID-oh-mide

Classifications

Therapeutic Classification: Immunosuppressant agents

Indications

REMS


Unlabeled Use:
  • Bechet’s syndrome.
  • HIV-associated wasting syndrome.
  • Aphthous stomatitis (including HIV associated).
  • Crohn’s disease.

Action

  • May suppress excess levels of tumor necrosis factor-alpha and alter leukocyte migration by altering characteristics of cell surfaces.
Therapeutic effects:
  • Decreased skin lesions in erythema nodosum leprosum and prevention of recurrence.
  • Slowed progression of multiple myeloma.

Pharmacokinetics

Absorption: 67–93% absorbed following oral administration.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Hydrolyzed in plasma to multiple metabolites. Primarily excreted in the urine (92%; <4% as unchanged drug).

Half-Life: 5–7 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2–5 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Erythema Nodosum Leprosum

Multiple Myeloma

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Thalomid